These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21119031)

  • 1. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
    Harris CA; Ward RL; Dobbins TA; Drew AK; Pearson S
    Ann Oncol; 2011 Jun; 22(6):1308-1317. PubMed ID: 21119031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
    Riemsma R; Forbes CA; Amonkar MM; Lykopoulos K; Diaz JR; Kleijnen J; Rea DW
    Curr Med Res Opin; 2012 Aug; 28(8):1263-79. PubMed ID: 22738819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
    Fleeman N; Bagust A; Boland A; Dickson R; Dundar Y; Moonan M; Oyee J; Blundell M; Davis H; Armstrong A; Thorp N
    Health Technol Assess; 2011; 15(42):1-93, iii-iv. PubMed ID: 22152751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
    Xie BJ; Zhu LN; Ma C; Li JB; Dong L; Zhu ZN; Ding T; Gu XS
    Breast Cancer; 2020 Mar; 27(2):186-196. PubMed ID: 31529262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-positive metastatic breast cancer: a changing scenario.
    Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
    Zhu ZL; Zhang J; Chen ML; Li K
    Asian Pac J Cancer Prev; 2013; 14(12):7111-6. PubMed ID: 24460260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
    DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
    Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
    Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
    J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.
    Pizzuti L; Sergi D; Barba M; Vici P
    Tumori; 2013; 99(3):e127-30. PubMed ID: 24158082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
    Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
    Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.
    Carli P; Militello L; Miolo GM; Quitadamo D; Lombardi D; Torrisi E; Scalone S; Crivellari D; Spazzapan S
    Tumori; 2014; 100(6):605-11. PubMed ID: 25688493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
    Madden R; Kosari S; Peterson GM; Bagheri N; Thomas J
    Int J Clin Pharmacol Ther; 2018 Feb; 56(2):72-80. PubMed ID: 29231164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
    J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
    Frampton JE
    Drugs; 2009 Oct; 69(15):2125-48. PubMed ID: 19791830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.